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summARy – Varicella zoster virus reactivation often occurs in the setting of impaired immu-
nity, which is generally present in patients with end-stage renal disease (esRd). Therapy for varice-
lla zoster virus infection is well established. however, it is often been forgotten that acyclovir dosage 
should be adjusted to renal function. We point to the problem encountered in clinical practice when 
esRd patient presents with cutaneous herpes zoster and neurological symptoms. Clinical findings 
alone may prove inadequate to determine whether neurological deficit is caused by infection of the 
central nervous system or is a consequence of acyclovir induced neurotoxicity.
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Varicella zoster virus (VzV) is an important patho-
gen in patients with deficient cellular immunity such 
as patients with end-stage renal disease (esRd). it is 
known that patients with esRd exhibit defective cel-
lular immunity, which is more affected than humoral 
immunity. immune deficiency due to uremia cannot 
be corrected by hemodialysis1. Reactivation of VzV 
usually gives rise to dermatomal unilateral cutaneous 
herpes zoster. neurological sequels of herpes zoster 
reactivation are infrequent except for post-herpetic 
neuralgia. epidemiological studies have identified a 
risk of 0.5%-1% for encephalitis or cerebral vasculitis 
in patients with herpes zoster2,3.
Acyclovir is a widely used and generally well toler-
ated antiviral agent. it is used with good success for 
herpetic infections. neurotoxicity associated with 
acyclovir use is infrequently encountered4. We de-
scribe three cases of hemodialysis patients with VzV 
reactivation referred to our center. 
Patients and Methods
data were obtained by searching medical records 
and protocols of hemodialysis. Age, sex, time on dial-
ysis, primary renal disease, comorbidities and detailed 
clinical characteristics of VzV infection were noted 
(localization, dissemination, complication and out-
come). diagnosis was based on clinical grounds and 
serology tests.
Results 
We had three patients with VzV reactivation, two 
female and one male, aged 61-78 years, treated with 
hemodialysis (table 1). two of them had received cor-
ticosteroids for their primary renal disease. At first, 
they had cutaneous manifestation of VzV reactiva-
tion, later followed by other complications.
our female patient had a history of hypertension, 
coronary artery disease and esRd due to endemic 
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nephropathy. Continuous ambulatory peritoneal di-
alysis (CApd) was initiated first, in 1995, and from 
2003 she was treated with hemodialysis three times a 
week. she developed typical herpes zoster eruptions 
on the right side of her head and neck. dermatolo-
gist prescribed acyclovir in a dose of 5x800 mg. two 
days after starting therapy, the patient came to hemo-
dialysis confused and disoriented. After four hours of 
hemodialysis, the patient had normal mental status. 
We suspected the signs of acyclovir neurotoxicity to 
be due to the full dose of acyclovir and the dose was 
reduced immediately. upon acyclovir dose reduction 
according to her renal function, the patient had no 
similar symptoms and her cutaneous herpes recovered 
completely in two weeks.
The second case was a 61-year-old male with 
AnCA+, anti GBm+ extracapillary glomerulone-
phritis who had been on chronic hemodialysis from 
2009. he received corticosteroids because of his pri-
mary renal disease and for prevention of pulmonary 
complications. he was admitted to department for 
infectious diseases because of disseminated cutane-
ous herpes zoster and parenteral acyclovir therapy was 
initiated immediately. shortly thereafter, clinical de-
terioration ensued as the patient developed a comatose 
mental state. Analysis of cerebrospinal fluid (Csf) 
obtained by lumbar puncture revealed pleocytosis and 
the polymerase chain reaction analysis (pCR) of the 
Csf detected VzV. After three weeks of therapy, his 
clinical status improved, however, shortly thereafter 
followed by recurrent infections and the patient died 
five months later.
The third case was a 72-year-old female whose pri-
mary renal disease was amyloidosis and she was also on 
corticosteroid therapy. Concomitant diseases included 
hypothyroidism and hypertension. she presented to 
our dialysis unit with cutaneous herpes zoster erup-
tions on her left arm. oral acyclovir 800 mg twice a 
day was prescribed. four days later, she was admit-
ted to neurological emergency unit because of global 
amnesia and confusion. Computed tomography (Ct) 
scan showed a hypodense zone, diagnosed as transient 
ischemic attack. on the next day, during hemodialy-
sis session, fluctuating and altered mental state was 
observed and the patient was referred to department 
of infectious diseases for suspicion of Cns infection. 
Analysis of Csf revealed pleocytosis. Repeated Ct 
scan revealed edema of the basal temporal lobe. After 
three weeks of therapy with parenteral acyclovir, full 
recovery followed and there were no changes on Ct 
scan.
Table 1. Characteristics of chronic hemodialysis patients with herpes zoster infection
Characteristic Case 1 Case 2 Case 3
Age (yrs)                                                  78 61 72
sex                                                                                               female male female
dialysis type                                     hemodialysis hemodialysis hemodialysis
dialysis duration (yrs)                      16 2 2
esRd etiology                               endemic nephropathy extracapillary Gn Amyloidosis
Comorbidity                                    Ah, CVd Ah Ah, hypothyroidism
first symptom(s)                           dermal rash dermal rash dermal rash
neurological symptom(s)          Confusion Comatose mental state, confusion disorientation, global amnesia
diagnosis                                                          Clinical Clinical, Csf, pCR Clinical, Csf, Ct
Therapy                                             Acyclovir oral Acyclovir parenteral Acyclovir oral, then parenteral
Clinical outcome                               full recovery fatal full recovery
esRd = end-stage renal disease; Ah = arterial hypertension; CVd = cardiovascular disease; Csf = cerebrospinal fluid; pCR = polymerase chain reaction; 
Gn = glomerulonephritis
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Discussion
Very few data exist on the occurrence of neuro-
logical complications of herpes zoster among patients 
with esRd or those undergoing dialysis. Varicella 
zoster virus encephalitis can be difficult to diagnose 
in immunocompromised hosts since cutaneous symp-
toms frequently lag behind or do not appear at all5,6. 
in such cases, the diagnosis can easily be overlooked, 
as other signs and symptoms are not specific. Clini-
cal features include headache, fever, vomiting, mental 
changes, seizures and focal deficits.
uremia is associated with lymphocytopenia and 
impaired lymphocyte function. Both t and B cells are 
affected. decreased chemotaxis results in impaired 
acute inflammatory response and decreased cell me-
diated (delayed type) hypersensitivity7. As a result, pa-
tients with esRd undergoing chronic hemodialysis 
are considered immunocompromised hosts and have 
higher susceptibility to infection and complications.
treatment of herpes zoster in patients with esRd 
requires special attention. Acyclovir is an effective 
agent for the treatment of VzV infection but is asso-
ciated with significant neurotoxicity when renal clear-
ance is reduced. Acyclovir is mainly eliminated by the 
kidney. it is estimated that the bioavailability of an 
oral dose of acyclovir is 15% to 30%. Acyclovir half-
life is greatly prolonged in patients with esRd, from 
normal 3 hours in adults with normal renal function 
to more than 20 hours in uremic patients, predispos-
ing this group to neurological side effects that are oc-
casionally severe, but generally reversible8.
it is often difficult to distinguish between herpes 
zoster encephalitis and acyclovir neurotoxicity on the 
basis of clinical findings alone. The occurrence of 
acyclovir induced encephalopathy can become a con-
founder in the clinical presentation of herpes zoster 
associated encephalitis. 
in our case, acyclovir was prescribed in full dose 
and neurological symptoms started two days after 
therapy administration. improvement of neurologi-
cal state after four hours of hemodialysis pointed to 
drug toxicity rather than infection. in the other two 
cases, infection was confirmed by Csf analysis and 
Ct scan, nevertheless, it cannot be excluded that the 
high serum acyclovir levels contributed to prolonged 
neurological impairment in our patient. unfortunate-
ly, there is no possibility to measure serum acyclovir 
level, which is normally 0.2-4 µg/ml. Therefore, dose 
adjustments are recommended for this population. for 
patient undergoing hemodialysis, the recommended 
dose is 800 mg twice daily9. 
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sažetak 
ReAKtiViRAnJe ViRusA heRpes zosteRA u BolesniKA liJečenih hemodiJAlizom: 
očitoVAnJe, liJečenJe, KompliKACiJe i ishod
I. Mesar, N. Bašić-Jukić, T. Hudolin, L. Katalinić i P. Kes
do reaktiviranja varicella zoster virusa dolazi u bolesnika s narušenim imunim sustavom, što je gotovo univerzalna 
pojava u bolesnika sa završnim stadijem kronične bubrežne bolesti. iako je liječenje infekcije varicella zoster virusom dobro 
poznato, često se zaboravlja da je potrebna prilagodba doze aciklovira s obzirom na bubrežnu funkciju. Želimo naglasiti 
problem pojave kožnog oblika herpes zostera u kombinaciji s neurološkim simptomima. na osnovi kliničkog nalaza pone-
kad nije moguće jasno razabrati radi li se o infekciji središnjega živčanog sustava ili o neurotoksičnosti aciklovira.
Ključne riječi: Encefalitis, varicella zoster; Antivirusni lijekovi; Bubrežno zatajenje, kronično
